Howard Goldschmidt, MD
Cardiovascular Disease · Ridgewood, NJNPI 1619940038
Payments from drug & device makers
Across 273 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abbott$2K
- Pfizer$443
- Novartis$362
- Boehringer Ingelheim$356
- Johnson & Johnson$305
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$2003%
- Travel & lodging$2,25030%
- Food & beverage$4,91366%
- Education$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 10 | $1,780 |
| Abbott | 16 | $1,509 |
| Pfizer | 33 | $443 |
| Novartis | 25 | $362 |
| Boehringer Ingelheim | 25 | $356 |
| Johnson & Johnson | 13 | $305 |
| Sanofi-aventis U.S. LLC | 19 | $278 |
| Boston Scientific | 13 | $263 |
| Amgen | 19 | $253 |
| E.r. Squibb & Sons, L.L.C. | 15 | $209 |
| AstraZeneca | 11 | $205 |
| Vifor Pharma, Inc. | 1 | $200 |
| Arbor Pharmaceuticals, Inc. | 14 | $170 |
| Regeneron Healthcare Solutions, Inc. | 12 | $163 |
| Novo Nordisk | 4 | $159 |
| Kowa Pharmaceuticals America, Inc. | 12 | $151 |
| Medtronic | 1 | $149 |
| Amarin Pharma, Inc. | 8 | $117 |
| Cvrx, Inc. | 5 | $97 |
| Merck | 5 | $68 |
| Abiomed | 1 | $41 |
| Heartflow, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $27 |
| Preventice Services, LLC | 1 | $25 |
| Irhythm Technologies, Inc. | 2 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVOQUE$869
- Veltassa$200
- Valiant Captivia$149
- XARELTO$147
- CARDIOMEMS$129
- Wegovy$113
How this compares
$7,446 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 391 | $420,406 |
| EliquisApixaban | 398 | $347,993 |
| VyndamaxTafamidis | 13 | $280,611 |
| JardianceEmpagliflozin | 215 | $185,897 |
| EntrestoSacubitril/Valsartan | 130 | $149,726 |
| MultaqDronedarone Hcl | 69 | $84,144 |
| BrilintaTicagrelor | 69 | $52,901 |
| Repatha SureclickEvolocumab | 16 | $25,461 |
| Praluent PenAlirocumab | 20 | $17,062 |
| Metoprolol Succinate | 722 | $11,176 |
| LivaloPitavastatin Calcium | 24 | $10,364 |
| Rosuvastatin Calcium | 643 | $10,072 |
| VascepaIcosapent Ethyl | 18 | $9,430 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 35 | $9,129 |
| Atorvastatin Calcium | 535 | $6,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $443 | $628,605411 claims |
| Johnson & JohnsonXarelto | $305 | $420,406391 claims |
| Boehringer IngelheimJardiance | $356 | $185,897215 claims |
| NovartisEntresto | $362 | $149,726130 claims |
| Sanofi-aventis U.S. LLCMultaq | $278 | $84,14469 claims |
| AstraZenecaBrilinta | $205 | $52,90169 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $151 | $10,36424 claims |
| MerckJanuvia | $68 | $6,19911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Ridgewood
- Kariann AbbateRidgewood$380K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.